Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 77.20 | 26.75 | 28.50 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.22 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.15 | 12.16 | 10.72 | 13.02 | 71.65 | 83.44 | 122.94 | 81.63 | 68.91 | 68.54 | 139.03 | 84.83 | 67.91 | 63.98 | 40.35 | 32.90 | 44.87 | 6.36 | 23.07 | 19.10 | 50.17 |
| — | -85.4% | -91.3% | -84.0% | +4.0% | +21.7% | -11.6% | -3.8% | +1.5% | +7.1% | +244.5% | +157.9% | +51.4% | +905.9% | +74.9% | +72.2% | -10.6% | -91.5% | -72.9% | -80.3% | +113.4% | |
| P/B Ratio | 65.14 | 43.02 | 54.11 | 59.86 | 62.56 | 23.29 | — | — | 8.52 | 4.72 | 9.24 | 3.72 | 2.81 | 2.39 | 1.72 | 1.32 | 2.51 | 2.98 | 4.83 | 5.70 | 6.89 |
| — | +84.7% | — | — | +634.6% | +393.7% | — | — | +202.6% | +97.5% | +438.3% | +181.6% | +12.3% | -19.9% | -64.4% | -76.8% | -63.6% | -60.6% | -40.8% | -25.2% | -74.6% | |
| P/FCF | — | 78.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 43.64 | 23.19 | 25.69 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 23.67 | 26.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 37.1% | 91.2% | 94.9% | 87.6% | 58.1% | 53.7% | -81.7% | -5.8% | 1.8% | -5.9% | -41.4% | -76.1% | -109.0% | -11.5% | 4.0% | 17.5% | 28.7% | 15.1% | 37.8% | -144.8% | -273.5% |
| — | +69.9% | +216.2% | +1606.5% | +3190.8% | +1013.8% | -97.1% | +92.4% | +101.6% | +48.7% | -1145.6% | -534.8% | -479.9% | -175.9% | -89.5% | +112.1% | +110.5% | -73.3% | -41.5% | +38.3% | -1053.8% | |
| Operating Margin | -1100.8% | 52.1% | 41.2% | -25.8% | -474.6% | -1180.0% | -3710.7% | -1685.0% | -2396.3% | -2231.1% | -8485.5% | -2292.3% | -1904.6% | -1518.3% | -1195.2% | -1268.4% | -1236.4% | -45.5% | -830.0% | -401.8% | -593.7% |
| — | +104.4% | +101.1% | +98.5% | +80.2% | +47.1% | +56.3% | +26.5% | -25.8% | -46.9% | -609.9% | -80.7% | -54.1% | -3234.5% | -44.0% | -215.7% | -108.2% | +93.0% | -20.8% | +57.5% | -3336.9% | |
| Net Margin | -2588.2% | 48.2% | 36.5% | -34.1% | -514.9% | -5008.4% | -3112.4% | -4038.3% | -1657.7% | -2516.1% | -8199.7% | -2228.9% | -2691.9% | -1435.5% | -1149.9% | -1228.2% | -1257.9% | 522.5% | -605.8% | -349.2% | -679.5% |
| — | +101.0% | +101.2% | +99.2% | +68.9% | -99.1% | +62.0% | -81.2% | +38.4% | -75.3% | -613.1% | -81.5% | -114.0% | -374.7% | -89.8% | -251.7% | -85.1% | +158.5% | -15.3% | +30.7% | -215.3% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -843.6% | 56.2% | 62.9% | -38.5% | -74.9% | -5751.4% | — | -442.9% | -42.0% | -48.7% | -83.9% | -22.0% | -24.8% | -12.6% | -11.6% | -14.6% | -16.5% | 88.2% | -27.2% | -21.3% | -21.0% |
| — | +101.0% | — | +91.3% | -78.2% | -11718.7% | — | -1910.6% | -69.2% | -285.8% | -623.1% | -50.4% | -50.5% | -114.3% | +57.4% | +31.1% | +21.4% | +530.2% | -126.9% | -48.5% | +68.3% | |
| ROA | -166.1% | 18.7% | 13.0% | -5.4% | -14.3% | -107.1% | -23.1% | -39.5% | -17.2% | -30.6% | -56.5% | -16.6% | -19.3% | -9.9% | -9.0% | -9.9% | -9.3% | 30.1% | -5.4% | -5.5% | -6.8% |
| — | +117.5% | +156.3% | +86.4% | +16.9% | -250.0% | +59.1% | -138.0% | +10.8% | -208.0% | -524.7% | -67.1% | -107.3% | -133.0% | -68.5% | -79.5% | -37.3% | +494.2% | -8.4% | -15.3% | +46.9% | |
| ROIC | -154.5% | 19.8% | 14.4% | -4.5% | -15.1% | -64.4% | — | — | -84.0% | -41.7% | -72.2% | -17.9% | -13.3% | -10.4% | -9.0% | -9.5% | -10.4% | -3.2% | -7.6% | -6.4% | -5.9% |
| — | +130.7% | — | — | +82.0% | -54.5% | — | — | -530.0% | -301.4% | -706.0% | -87.8% | -28.5% | -228.6% | -17.8% | -48.9% | -76.3% | +39.0% | -29.3% | +29.0% | -623.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.70 | 1.18 | 2.26 | 4.86 | 4.70 | 2.35 | — | — | 0.14 | 0.10 | 0.15 | 0.07 | 0.06 | 0.05 | 0.05 | 0.12 | 0.41 | 0.64 | 3.73 | 3.03 | 1.77 |
| — | -49.8% | — | — | +3190.2% | +2159.0% | — | — | +138.5% | +107.4% | +206.5% | -41.3% | -85.3% | -92.2% | -98.7% | -96.1% | -77.0% | -59.4% | +190.3% | +173.3% | -34.7% | |
| Debt / EBITDA | — | 2.48 | 4.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.09 | 5.58 | 4.58 | 4.82 | 3.09 | 4.04 | 2.71 | 3.53 | 4.76 | 1.63 | 1.03 | 1.72 | 2.99 | 2.83 | 3.43 | 2.95 | 1.50 | 1.55 | 5.51 | 6.05 | 4.52 |
| — | +38.0% | +69.2% | +36.6% | -35.1% | +148.4% | +162.7% | +104.8% | +59.1% | -42.5% | -70.0% | -41.6% | +99.1% | +82.2% | -37.7% | -51.3% | -66.8% | -70.6% | +1.4% | +6.0% | +27.9% | |
| Quick Ratio | 2.83 | 4.83 | 3.89 | 4.12 | 2.83 | 3.95 | 2.71 | 3.53 | 4.76 | 1.63 | 1.03 | 1.72 | 2.99 | 2.83 | 3.43 | 2.95 | 1.50 | 1.55 | 5.50 | 5.55 | 4.51 |
| — | +22.5% | +43.7% | +16.8% | -40.5% | +142.6% | +162.7% | +104.8% | +59.1% | -42.5% | -70.0% | -41.6% | +99.6% | +82.4% | -37.6% | -46.9% | -66.8% | -68.6% | +9.3% | +5.0% | +38.1% | |
| Interest Coverage | -63.81 | 13.00 | 7.80 | -1.73 | -6.93 | -161.24 | — | -54152.00 | — | -11982.00 | -30239.50 | -11882.50 | -4768.71 | -19800.00 | -148.88 | -69.34 | -33.80 | -3.74 | -11.67 | -10.63 | -4.48 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PGEN stock.
Precigen, Inc.'s current P/E is 77.2x. The average P/E over the last 2 quarters is 27.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Precigen, Inc.'s current operating margin is -1100.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Precigen, Inc.'s business trajectory between earnings reports.